User profiles for "author:Pradip Bajgain"
Pradip BajgainNational Institutes of Health | National Cancer Institute Verified email at nih.gov Cited by 1096 |
[HTML][HTML] Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer
S Mohammed, S Sukumaran, P Bajgain, N Watanabe… - Molecular therapy, 2017 - cell.com
The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …
Fine-tuning the CAR spacer improves T-cell potency
N Watanabe, P Bajgain, S Sukumaran, S Ansari… - …, 2016 - Taylor & Francis
The adoptive transfer of genetically engineered T cells expressing chimeric antigen
receptors (CARs) has emerged as a transformative cancer therapy with curative potential …
receptors (CARs) has emerged as a transformative cancer therapy with curative potential …
[HTML][HTML] Optimizing the production of suspension cells using the G-Rex “M” series
P Bajgain, R Mucharla, J Wilson, D Welch… - … Therapy Methods & …, 2014 - cell.com
Broader implementation of cell-based therapies has been hindered by the logistics
associated with the expansion of clinically relevant cell numbers ex vivo. To overcome this …
associated with the expansion of clinically relevant cell numbers ex vivo. To overcome this …
[HTML][HTML] Kinetics of tumor destruction by chimeric antigen receptor-modified T cells
U Anurathapan, RC Chan, HF Hindi, R Mucharla… - Molecular Therapy, 2014 - cell.com
The use of chimeric antigen receptor (CAR)–modified T cells as a therapy for hematologic
malignancies and solid tumors is becoming more widespread. However, the infusion of a T …
malignancies and solid tumors is becoming more widespread. However, the infusion of a T …
Enhancing the potency and specificity of engineered T cells for cancer treatment
S Sukumaran, N Watanabe, P Bajgain, K Raja… - Cancer discovery, 2018 - AACR
The adoptive transfer of chimeric antigen receptor (CAR)–modified T cells has produced
tumor responses even in patients with refractory diseases. However, the paucity of antigens …
tumor responses even in patients with refractory diseases. However, the paucity of antigens …
[HTML][HTML] CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
P Bajgain, S Tawinwung, L D'Elia… - … for immunotherapy of …, 2018 - Springer
Background The adoptive transfer of T cells redirected to tumor via chimeric antigen
receptors (CARs) has produced clinical benefits for the treatment of hematologic diseases …
receptors (CARs) has produced clinical benefits for the treatment of hematologic diseases …
[HTML][HTML] Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
Background Successful targeting of solid tumors such as breast cancer (BC) using chimeric
antigen receptor (CAR) T cells has proven challenging, largely attributed to the …
antigen receptor (CAR) T cells has proven challenging, largely attributed to the …
[HTML][HTML] Cancer cell survival depends on collagen uptake into tumor-associated stroma
KS Hsu, JM Dunleavey, C Szot, L Yang… - Nature …, 2022 - nature.com
Collagen I, the most abundant protein in humans, is ubiquitous in solid tumors where it
provides a rich source of exploitable metabolic fuel for cancer cells. While tumor cells were …
provides a rich source of exploitable metabolic fuel for cancer cells. While tumor cells were …
Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform
The majority of clinically approved drugs target proteins that are secreted or cell surface
bound. However, further advances in this area have been hindered by the challenging …
bound. However, further advances in this area have been hindered by the challenging …
Secreted Fas decoys enhance the antitumor activity of engineered and bystander T cells in Fas ligand–expressing solid tumors
P Bajgain, AG Torres Chavez… - Cancer immunology …, 2022 - AACR
T-cell immunotherapy has demonstrated remarkable clinical outcomes in certain
hematologic malignancies. However, efficacy in solid tumors has been suboptimal, partially …
hematologic malignancies. However, efficacy in solid tumors has been suboptimal, partially …